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Abstract
Migraine, characterized by recurrent attacks of predominantly unilateral throbbing
headache, affects approximately 15% of the adult population and is an important
cause of disability worldwide. Knowledge required for the development of new clas-
ses of antimigraine drugs might come from studying rare metabolic diseases associ-
ated with migraine. An illustrative example of a monogenetic disorder associated with
migraine is the spectrum of disorders caused by the m.3243A>G mutation in
the mitochondrial transfer RNA Leucine. Reported migraine prevalence figures in
patients with this particular mutation vary considerably, but compared to the general
population, m.3243A>G patients have a higher migraine prevalence. This burden-
some symptom might sometimes even be the only clinical feature in maternal rela-
tives carrying the m.3243A>G mutation. Although the exact sequence of events and
the relative importance of factors underlying migraine in m.3243A>G MELAS spec-
trum disorders are still enigmatic, substantial evidence in man exist that dysfunctional
mitochondria in both the vascular, the smooth muscle cells and the neuronal system
and the interaction between these are at the starting point of the migraine developing
pathophysiological cascade. Exclusively based on results of studies performed in
patients harboring the m.3243A>G mutation, either in vivo or ex vivo, we here sum-
marize our current understanding of mitochondrial angiopathy associated migraine in
m.3243A>G patients which knowledge might lead to potential new avenues for
migraine drug development.
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1 | INTRODUCTION
Migraine is a frequently occurring, debilitating form of
headache causing a huge socioeconomic burden. Severity
ranges from occasional or temporary migraine without aura
up to chronic migraine. The underlying pathology of mi-
graine headache is a complex process that demands the
recruitment of an intricate set of central nervous system
components.25 The current view is that activation of the tri-
geminovascular system, consisting of nociceptive trigeminal
sensory afferents surrounding cranial blood vessels, plays an
important role in it.6,7,16 Pial, dural, and extracranial vessels
are part of this system that releases vasoactive neuropeptides
from perivascular sensory (pain) nerve fibers and reacts to
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them with pain sensation (nociception) and vasodilatation.6
The fact that all migraine-provoking molecules are vasoac-
tive and the serotonin 5-HT receptor agonists like sumatrip-
tan constricts arteries further granted a key role of cranial
vasculature in migraine pathophysiology.79 Some authors
have questioned the vascular hypothesis of migraine and
proposed that the cranial arteries response is a negligible
epiphenomenon.6
The complex pathophysiology of migraine, which is consid-
ered to be a polygenetic disease with environmental modifiers,
is the main reason for the paucity of migraine-specific treat-
ments.37 Experimental models of migraine in humans, like
those that exploit prostaglandin synthesis, have contributed to
the discovery of key molecular pathways and the identification
of biomarkers and drug targets.4 Current paradigms explaining
migraine are based on a mixture of results obtained via in
vitro experiments in different cellular models, artificial in vivo
models and studies in humans, both ex vivo and in vivo.
Here we review the complex relationship between migraine
and mitochondria in patients with the spectrum of disorders
caused by the m.3243A>G mutation in the tRNALeu[UUR] an
association which has also been disputed.14,15,23 Importantly,
the results in this review, and the hypothesis presented, are
not based on cellular models or migraine in vivo models
but are exclusively based on results of studies performed in
patients harboring the m.3243A>G mutation, either in vivo
or ex vivo.
2 | MITOCHONDRIA: STRUCTURE,
FUNCTION, AND PATHOLOGY
Mitochondria, double-membrane bound subcellular organelles,
are present in every cell of the body except for erythrocytes.68
As the brain is a high-energy consuming organ, brain cells rely
heavily on proper mitochondrial functioning. Traditionally,
although many more functions are now attributed to it,
mitochondria are described as cellular powerhouses.44 The
OXPHOS consists of five multi-protein complexes, varying in
size from 4 to 44 proteins, and two electron carriers (ubiqui-
none and cytochrome c). The system is under dual-genetic con-
trol. In the past 20 years, mutations in more than 250 genes
affecting OXPHOS functioning have been characterized lead-
ing to a great variety in clinical disease expression.30 The direct
biochemical consequences of these mutations are isolated or
combined OXPHOS complex deficiencies causing not only
decreased ATP production but also a disturbed redox-state,
increased reactive oxygen species production and abnormal
cellular calcium handling to name a few.43
During the normal production of ATP, the OXPHOS gener-
ates ROS in the form of superoxide through the transfer of
excessive electrons to oxygen at specific sites. The most impor-
tant sites are located in complexes I and III. Mitochondrial
ROS represent 90% of total cellular ROS. Under normal condi-
tions highly reactive superoxide is detoxified by the superoxide
dismutase enzymes into hydrogen peroxide (H2O2), a central
signaling molecule, which can be further transformed to water
by catalase, glutathione peroxidase, or peroxiredoxin enzymes.
While ROS play an important role in cell signaling, disturbance
in their production level, due to OXPHOS deficiencies, can
lead to oxidative stress. Excessive superoxide can react with
H2O2 or nitric oxide (NO), forming respectively the hydroxide
radical (OH•) and peroxinitrite (ONOO ). Both reactive radi-
cals can damage macromolecules such as lipids. Oxidative
stress is implicated in the pathomechanism of several diseases,
including migraine.28
3 | MITOCHONDRIAL DISEASES,
MIGRAINE, AND THE M.3243A>G
MUTATION
Mitochondrial diseases (MDs) are multi-system disorders
caused by defective oxidative phosphorylation in which the
brain, as a high-energy consuming organ, is frequently
affected. Although the brain weight/body weight ratio is low
(an adult brain weighing approximately 1.5 kg), the brain
consumes 20% of oxygen and 50% of glucose delivered
from the vasculature for ATP synthesis.5 Neuronal cells rely
heavily on OXPHOS while glial cells also contain glycogen
as an energy source.47 Most energy consumption in the brain
is used for synaptic transmission and delivered by mitochon-
dria, preferentially localized to pre- and postsynaptic sites.
The range of central nervous system manifestations in
MD is broad.76 Migraine is a frequently reported symptom,
especially in m.3243A>G spectrum disorders. M.3243A>G
patients have higher migraine prevalence than the general
population.61 Migraine is sometimes even be the only clini-
cal feature in maternal relatives carrying the m3243A>G
mutation.19
Reported migraine prevalence figures in m.3243A>G
patients vary considerably. One explanation for these observed
differences in reported migraine prevalence figures in
m.3243A>G patients is that, based even on the mutation only,
a spectrum of disorders has been included in the studies,
thereby not discriminating for example, classical MELAS
patients with stroke-like episodes from maternally inherited
diabetes and deafness (MIDD) patients, of which the former
population is more severely affected and more likely to exhibit
migraine. Besides, differences in data gathering via the use or
nonuse of specific questionnaires, interviews, and clinical
examination might have contributed to the reported differ-
ences.1,22,33,46,51,52,61,83 In cohort studies using the NMDAS
(Newcastle Mitochondrial Disease Score: Section II—System
Specific Involvement) questionnaire, migraine was present in
~18%-29% of the patients.22,51,62 These figures are
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significantly lower than in three recently published large stud-
ies in which (adult) patients underwent a structured diagnostic
headache interview using an operational diagnostic tool fol-
lowing the International Headache Society criteria.33,83 In
patients harboring the m.3243A>G mutation (associated with
for example, MELAS syndrome) the percentage of migraine
ranged between 38% and 85%.33 (Table 1).
The frequency of migraine headache described in these
studies varied from once per month to more than 20 episodes
per month. Many patients with migraine and probable
migraine show accompanying symptoms such as vomiting,
photo-, phonophobia, or an increase of headache following
physical activity. It has been reported that the duration of
attacks in patients with mitochondrial migraine was shorter
than in patients with non-mitochondrial migraine.
Potentially raised ROS in neurons and cerebral vasculature
due to OXPHOS deficiency will have a major impact, also due
to the fact that brain tissue by itself is susceptible to oxidative
stress (for reviews see12,28). Ex vivo indications of increased
ROS or its consequences in m.3243A>G patients have been
obtained by studying serum samples of 14 patients with this
mutation showing increased mean levels of daicron-reactive
oxygen metabolites (d-ROMS) and lowered biological antioxi-
dant potential (BAP)/d-ROMS ratio.40 In non-mitochondrial
migraine patients increased oxidative stress markers like mal-
ondialdehyde, total antioxidant activity, GSH/GSSG concen-
trations were observed as were decreased concentrations of
plasma GSH, glutathionine-S-transferase (GST), and total anti-
oxidant capacity compared to controls.40,80
PET imaging with 56Cu-ATSM and 18FDG demonstrated
increased oxidative stress and increased glucose metabolism
following hyperemia in a MELAS syndrome patient with
stroke-like episodes.41 Importantly, to our best knowledge, so
far none of these imaging studies have been done in migraine
m.3243A>G patients without stroke-like episodes. More
advanced ROS detecting imaging probes like MitoNeoD, cur-
rently still under investigation in animal models, might con-
tribute to a better understanding of the complex relationship
between ROS-redox metabolism, mitochondrial dysfunction
and mitochondrial migraine.73
4 | ANATOMICAL,
PATHOLOGICAL, BIOCHEMICAL,
CELL BIOLOGICAL, AND
ELECTROPHYSIOLOGICAL
FINDINGS IN THE BRAINS OF
M.3243A>G PATIENTS
Montagna and coworkers were among the first to suggest an
association between mitochondrial dysfunction and migraine.58
Yorns and Hardison summarized the different types of evi-
dence between mitochondrial dysfunction (biochemical, mor-
phological, genetic, and therapeutic) further supporting an
association between mitochondria and migraine.85 Since then,
numerous others pinpointed to this association (for a recent
review see Ferroni et al.28).
An important question is what explains the high prevalence
of migraine headache in m.3243A>G patients or in other
words what is the underlying pathophysiological mechanism?
Here, we aim to answer this question based on available data
in literature in humans. The reasons to focus on patients with
the m.3243A>G mutation is based on, the m.3243A>G muta-
tion prevalence from 7.59 to 236/100.000,17,49,54 on the rela-
tively high prevalence of migraine in syndromes caused by the
m.3243A>G mutation and on the relatively high number and
variety of brain investigations performed in this patient popu-
lation. Figure 1 summarizes the most important pathological,
biochemical and neuro-imaging abnormalities observed in
m.3243A>G patients.
4.1 | The m.3243A>G mutation causes a
spectrum of disorders
The first report mentioning migraine in MELAS patients dates
back from 1988.57 The acronym MELAS (mitochondrial
encephalopathy, lactic acidosis, and stroke-like episodes) was
first described as a separate disease entity more than 30 years
ago.66 The disease causing mutation, an A-to-G transition at
nucleotide pair 3243 in the dihydrouridine loop of the mito-
chondrial tRNALeu(UUR) was reported 6 years later.32
Our current understanding is that theMT-TL1 m.3243A > G
mutation is associated with a spectrum of diseases involving
TABLE 1 Migraine in mitochondrial diseasea
Mutation Phenotype N total N headache/migraine (%) Type study Author year
m.3243A > G mixed 71 13 (18%) Prospective registry De Laat 201222
m.3243A > G mixed 129 30 (23%) Retrospective Nesbitt 201361
m.3242A > G mixed 133 35 (27.8%) Retrospective Mancuso 201451
m.3243A > G mixed 57 33 (58%) Questionnaire Guo 201633
m.3243A > G MELAS 8 7 (88%) Questionnaire Kraya 2017
m.3243A > G MELAS 13 5 (38%) Questionnaire Vollono 201783
aThe 1 year prevalence of migraine in the general population is 12%. The annual and lifetime prevalence are 18% and 33% in women, respectively, and 6 and 10% in men.24
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not only the classical MELAS presentation but also MIDD
(maternally inherited diabetes mellitus and deafness)21,38,53
with or without hypertrophic cardiomyopathy and renal failure,
CPEO36,59 and mixed-phenotypes showing a variety of differ-
ent complaints, signs and symptoms.81 One explanation for the
observed variation in phenotypic expression is “heteroplasmy”
where wild-type mitochondrial DNA coexists with mutated
molecules in the same cell and different cells have different het-
eroplasmy percentages.13
4.2 | Mitochondrial angiopathy: a frequent
finding at autopsy in MELAS syndrome
patients
The pathological features of MELAS syndrome include the
accumulation of abnormal mitochondria in endothelial cells
and smooth muscle cells of the pial arterioles, on the brain sur-
face and penetrating in the Virchow-Robin space, and in small
intracerebral arteries.39 In more contemporary wording “accu-
mulation” refers to an increased number of mitochondria that
might be caused by increased biogenesis, a phenomenon some-
times also encountered in skeletal muscle fibers and then
termed “ragged red fibers,” or by a decreased mitochondrial
autophagy referred to as “mitophagy.”69 The accumulated brain
vascular endothelial and smooth muscle cell mitochondria
may have abnormal sizes and shapes and inclusions, as seen in
skeletal muscle fibers of affected patients. Ohama et al.64 per-
formed systematically electron microscopy (EM) studies of the
cerebral blood vessels in two patients with MELAS (Table 2).
They found marked accumulation of mitochondria in the cell
bodies of smooth muscle cells and endothelial cells and numer-
ous smooth muscle cells showing degeneration or necrosis in
the tunica medica. These abnormalities, which they termed
mitochondrial angiopathy, were most prominent in the walls of
pial arterioles and small arteries up to 250 μm in diameter, and
less frequent and severe in the larger pial arteries and intracere-
bral arterioles and small arteries. Kishi et al42 performed
autopsy on a 30-year-old woman. EM of the brain capillaries
of this patient revealed hypertrophy of the endothelial cells,
increased mitochondria in the subendothelial space, and nar-
rowing of the capillary lumens. Mizukami et al. described the
autopsy in a 38-year-old male56 showing that both cerebral and
cerebellar blood vessels had marked aggregation of mitochon-
dria in smooth muscle cells and the vascular endothelium.
Bertrand et al.7 reported numerous focal and so called pseudo-
laminar cortical necrosis in the brain of a 27-year-old
MELAS patient, regardless of vascular supply, with character-
istic proliferation of capillary vessels. Brain at autopsy of a
47-year old woman with MELAS syndrome showed vascular
sclerosis, cerebral atrophy, diffuse cortical gliosis, basal ganglia
calcifications, and a small remote left temporal lobe infarct.67
The molecular neuropathology of two patients with the
FIGURE 1 Pathological, neuroimaging, and biochemical features associated with mitochondrial migraine
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m.3243A > G mutation showed that the most severe COX
deficiency associated with the highest proportion of mutated
mitochondrial DNA was present in the walls of the leptome-
ningeal and cortical blood vessels in all brain regions.8,20,31
Betts and coworkers concluded that vascular mitochondrial
dysfunction is important in the pathogenesis of the stroke-like
episodes in MELAS patients. They suggested, as migraine is a
commonly encountered feature in MELAS syndrome, that the
vascular mitochondrial dysfunction together with cortical
spreading depression (CSD) might underlie the selective distri-
bution of ischemic lesions in the posterior cortex in these
patients.8 Filosto et al. compared the neuropathology of six dif-
ferent mitochondrial diseases with respect to the distribution
and severity of the lesions.29 In MELAS syndrome the cortex
was most involved followed by multisystem degeneration and
to a lesser degree the sub-cortical structures. Multifocal infarct-
like lesions in the occipital, parietal, and temporal cortices
associated with neuronal loss and gliosis was the most com-
mon neuropathological pattern in MELAS syndrome. Next to
that, mineral deposits in blood vessels of the basal ganglia and
capillary proliferation have been reported.8,71 Depending on
the size and distribution of the accumulation this might lead to
decreased vascular lumina, increased vascular wall stiffness
and disturbed perfusion.
4.3 | Neuro-imaging in m.3243A>G migraine
patients
Different types of imaging techniques have been used to
study the brain of migraine patients.50 These include con-
ventional imaging techniques (Computed Tomography and
Magnetic Resonance Imaging/Spectroscopy and Cerebral
Angiography), cerebral perfusion imaging techniques
(Position Emission Tomography, Single-Photon Emission
Computed Tomography, Arterial Spin Labeling), novel
imaging techniques (Oxygen Extraction Fraction) and Dif-
fusion Tensor Imaging.82 In the m.3243A>G-caused
MELAS syndrome all these techniques have mainly been
used in the context of stroke-like episodes, but not in non
stroke-like-episode associated migraine.50 The number of
reports using brain single photon emission computed
tomography (SPECT) and DTI in m.3243A>G patients
without or outside stroke-like episodes are rare.70
99mTc-ECD SPECT studies conducted in three patients with
the m.3243A>G mutation, regardless of whether they had or
had not suffered from stroke-like episodes, showed multiple
areas of asymmetrical decreased perfusion (mitochondrial vas-
culopathy), particularly in the posterior and lateral head
regions, especially the temporal lobes. This mitochondrial vas-
culopathy with regional cerebral hypoperfusion may be seen
on brain 99mTc-ECD SPECT regardless of whether they have
or have not suffered from stroke-like episodes.78 Such inappro-
priate intracranial hemodynamics was also observed when
studying, over a period of 10 years, the natural course of five
MELAS patients with hypoperfusion in the posterior cingulate
cortex observed by 99 SPM-SPECT.63 More and longitudinally
repeated imaging studies using functional imaging technologies
in carriers of the m.3243A>G with migraine but without
stroke-like episodes are warranted.
4.4 | Ex vivo and in vivo brain OXPHOS
(bio-) chemistry consequences in m.3243A>G
patients
Using immunohistochemistry Sparaco and coworkers
showed reduced expression of COX-II and ATPase8 in
multiple brain areas of three unrelated m.3243A>G
patients.77 The topographic analysis allowed the authors to
draw some correlations between the immunohistochemical
and clinical and neuropathological features, like the dem-
onstration of a cortical mitochondrial dysfunction and the
preferential involvement of the cerebral cortex in
m.3243A>G patients. Betts et al.8 studied the neuropathol-
ogy in 2 m.3243A>G patients who both died of cardiac
failure. The main results were (a) a low number of COX-
deficient neurons in all brain regions, (b) no correlation
between the threshold level for the 3243A>G mutation to
cause complex IV deficiency within single neurons and the
degree of pathology in affected brain regions. They further-
more observed that the most severe complex IV deficiency
associated with the highest proportion of mutated mito-
chondrial DNA was present in the walls of the leptomenin-
geal and cortical blood vessels in all brain regions. As the
most immunohistochemical studies have mainly used COX
staining as OXPHOS read out general conclusions between
the m.3243A>G mutation, threshold and pathology should
TABLE 2 Mitochondrial angiopathy on electronmicroscopy in
m.3243A>G patients
REF
Mitochondrial accumulation in smooth
muscle and endothelial cells
Ohama et al 198864
Tunica media cell degeneration and
necrosis
Endothelial cell hypertrophy Kishi et al 198842
Increased number subendothelial
mitochondria
Narrowing capillary lumens
Marked aggregation of mitochondria
in smooth muscle cells and
vascular endothelium
Mizukami et al. 199256
Proliferation of capillary vessels Bertrand et al. 19967
Vascular sclerosis Prayson and Wang 198867
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be carefully interpreted. Indeed, it is known that due to this
specific mutation also the ROS producing complexes I and
III can be markedly affected. This is illustrated by Müller-
Höcker who described the results of autopsy in a nearly
13-year-old girl whose brain complex I activity was dimin-
ished to 20%,60 whereas complex IV was only slightly
below the low-normal range. It is also illustrated in a recent
article of Chrysostomou et al.18
5 | THE ROLE OF
MITOCHONDRIAL FUNCTIONING
IN MIGRAINE PATHOPHYSIOLOGY
5.1 | Role of oxidative stress in migraine
pathophysiology
Oxidative stress is implicated in the pathomechanism of sev-
eral diseases affecting the brain. This organ is highly suscep-
tible to oxidative damage, especially lipid peroxidation,
because of the high content of polyunsaturated fatty acids in
neurons. Elevated lipid peroxides and reduced levels of anti-
oxidant enzymes in migraine patients have an important role
of oxidative stress in the pathology of migraine (for a recent
review see Ferroni et al.28).
Next to a direct effect on for example, lipids, increased
ROS levels due to mitochondrial dysfunction can also lead to
the induction of a neuroinflammatory response through the
release of interleukin 1-beta and the consequent increase in
inflammatory mediators such as the prostaglandins (PG) and
prostanoids.45 An elevated level of PGE2, the majority lipid
mediator that contributes to inflammatory pain, has been
reported during migraine attacks in patients suffering from
migraines.3 Also, intravenous infusion of PGE2 was shown to
cause migraine-like symptoms in migraineurs.2 This highlights
the role of PGE2, which might occur as a consequence of
increased ROS production due to a disturbed OXPHOS, in the
pathophysiology of migraine.
5.2 | Endothelial shear and circumferential
wall stress
Blood vessels are under constant mechanical loading from
blood pressure and flow that cause internal stresses (endo-
thelial shear stress and circumferential wall stress, respec-
tively).48 Wu et al.84 showed mitochondrial increment in
cultured human umbilical vein endothelial cells subjected
to laminar shear stress (LSS). The translocation of
dynamin-related protein Drp1 to the mitochondria was de-
creased suggesting that LSS promotes mitochondrial
fusion. Besides, next to enhanced mitochondrial biogenesis
they observed an increased expression of mitochondrial
antioxidant enzymes and an increased mitochondrial
membrane potential and ATP generation. We hypothesize
that, based, on decreased perfusion in m.3243A>G patients
downstream of the induced mitochondrial vasculopathy,
decreased laminar shear stress causes disturbed mitochon-
drial homeostasis and ROS-induced, inflammation induced
impairments in brain vasculature (Figure 2). We postulate
that such a disturbed mitochondrial homeostasis, leading to
decreased biogenesis, expression of mitochondrial antioxi-
dant enzymes, membrane potential and ATP production,
might aggravate the preexisting mitochondrial dysfunction
present in brain vasculature and neuronal cells as a conse-
quence of the m.3243A>G mutation. Along these lines
Borgdorff proposed shear-induced platelet aggregation as
one of the initiators of a sequence of events leading to a
migraine attack.10 Shortly, increased shear stress might
lead to platelet aggregation in a narrowed vessel to the
brain or in the circle of Willis.11 The consequent release of
platelet serotonin may cause pain and dilatation of the
extracerebral arteries (migraine without aura) and in higher
concentrations may provoke vasoconstriction. This is com-
parable to glutamate induced gap-junctional slow calcium
waves in astrocyte syncytium, hypothesized to be responsi-
ble for the slowly preceding aura signs.9
5.3 | Cortical spreading depression
Zielman's hypothesis states that increased glutaminergic activ-
ity leads to an increased cerebral excitability and enhanced sus-
ceptibility to cortical spreading depolarization.27 Cortical
spreading depolarization or depression (CSD) is defined as a
slowly propagating (2-5 mm/min) wave of rapid near-complete
depolarization of neurons and astrocytes followed by a period
of electrical suppression of a distinct population of cortical neu-
rons.74 The link between CSD and migraine aura was sug-
gested by Milner55 and directly demonstrated using functional
MRI in a patient during a migraine attack.34 Cortical spreading
depression itself induces oxidative stress in the trigeminal noci-
ceptive system (Shatillo et al., Neuroscience 253, 341-349,
2013). Oxidative stress is also one of the consequences of ham-
pered OXPHOS.
5.4 | Nitric oxide, arginine and citrulline
The m.3243A>G mutation might lead to decreased NO syn-
thesis due to impaired citrulline and arginine synthesis.
Nitric oxide deficiency and consequently impaired microvas-
culature perfusion.26 To our best knowledge no randomized
controlled trials have been performed evaluating the effect
of arginine, citrulline, or a combination of both in the treat-
ment of mitochondrial migraine.
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6 | MITOCHONDRIAL MIGRAINE
IN M.3243A>G CARRIERS: PUTTING
BITS AND PIECES TOGETHER
Two possible pathophysiological mechanisms for migraine
in mitochondrial disease have been proposed: mitochondrial
angiopathy and mitochondrial cytopathy. Both conditions, if
caused by an oxidative phosphorylation defect, will affect
different cell types like endothelial and smooth muscle cells,
neurons, and glia cells, and are, in strictu sensu, both cytopa-
thies. As mitochondria play a key role in both the vascular
endothelial cells, neurons and glia cells, and smooth muscle
cells, the exact sequence of events finally causing migraine
will be difficult to decipher. Most probably the pathological
cellular consequences of mitochondrial dysfunction will act
in parallel, interact with each other, be dependent on the
involved cell type, might follow a different time-scale, and
will react differently on their environment. Based on avail-
able literature, with observations in humans, the following
cascade of events might (partially) explain the mitochondrial
m.3243A>G migraine association (Figure 3).
The first branch of our simplified migraine paradigm starts
with vascular smooth muscle and endothelial cortex cell angio-
pathy caused by the tRNALeu mutation. Among the cell bio-
logical consequences of disturbed OXPHOS belong increased
ROS and disturbed redox metabolism. Increased ROS induces
endothelial cell mitochondrial biogenesis and chemical inflam-
mation described as mitochondrial angiopathy.
Both the increased mitochondrial biogenesis and ROS-
induced inflammation and edema cause increased endothelial
cell volume leading to a focal constriction (narrowing) of the
lumen of the pial arterioles and small intracerebral arteries
(up to 250 μm). The degree of heteroplasmy in the vascular
endothelial cells presumably determines the magnitude of
FIGURE 2 Mitochondrial biogenesis and vascular shear stress. Based on the existing heteroplasmy percentage of mitochondrial DNA
molecules in m.3243A>G patients, heterotopic effects of the endothelial cells are expected. Mitochondrial biogenesis is induced by ROS. Proximal
of thereby increased shear and circumferential wall stress mitochondrial biogenesis is progressively increased. Besides, the increased shear and wall
stress may lead to platelet aggregation with serotonin release. Distal of the most affected endothelial cells, next to hypoxia/ischemia, decreased shear
stress is expected decreasing mitochondrial homeostasis and inducing inflammation. Wild type mitochondria are depicted in blue
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the narrowing due to its direct relationship with disturbed
OXPHOS. As the narrowing of the vessels will lead to the sub-
sequent effects in the proximal and distal vessel, the level of
heteroplasmy may be a determinant of migraine susceptibility.
The expected increased vascular pressure proximal of
the vascular narrowing causes enhanced laminar shear
stress which might further progress mitochondrial biogen-
esis and vascular narrowing. Shear stress itself might lead
to cortical spreading depolarization of neurons and astro-
cytes, a further increase of ROS, activation of the trigemi-
nal nociceptive system and finally migraine. Important
other mitochondrial-dysfunction related catalysts include
the increased glutamate in the visual cortex as a
consequence of the hampered oxidative phosphorylation
and the activation of nociceptive signaling via redox-
sensitive ion channels. Increased shear stress might also
lead to platelet aggregation and serotonin release in a nar-
rowed vessel to the brain or in the circle of Willis.11 The
serotonin release may cause pain and dilatation of the
extracerebral arteries (migraine without aura) and in
higher concentrations may provoke vasoconstriction and
thus being responsible for the slowly preceding aura
signs.9
Distal of the increased endothelial cell volume a decreased
shear stress is expected which might lead to decreased mito-
chondrial homeostasis and induces inflammation (Figure 3).
FIGURE 3 Proposed sequence of the mitochondrial disease migraine cascade. The percentages of the m.3243A > G mutation in
vascular endothelial and smooth muscle cells, neurons and glia like astrocytes may vary in and between the different cell types. Long-term
exposure of toxic substances, as ROS, might contribute to the occurrence of migraine at later age. The mutation, when having passed the
disease-elucidating threshold, will lead to a hampered OXPHOS due to defective translation. A disturbance of the OXPHOS complexes,
mainly complex I and III, will give rise to an increase in ROS and disturbed cellular redox-state which cannot be compensated by the natural
existent scavenger system like the superoxide dismutases. Presumably as an adaptive consequence to the altered mitochondrial architecture
caused by increased lipid peroxidation, its decreased ATP generating capacity and other cell biological consequences, the affected cells will
initially respond via increased mitochondrial biogenesis. In brain vascular endothelial and smooth cells narrowing of the lumen will take place
(for further details see Figure 2). Next to the increased production of ROS the consequent hypoxia/ischemia, altered glutamate metabolism and
ionic homeostasis might trigger cortical spreading depolarization (CSD). CSD is an activator of the trigeminovascular system leading to
migraine pain27
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7 | NEW ANCHORS FOR
MITOCHONDRIAL MIGRAINE
TREATMENTS AND TRIAL DESIGN
The first Pubmed report on treatment of migraine dates from
1888.35 Since then various new treatment modalities have
become available for which we refer to recent reviews and
guidelines.16,65,75 Based on the disentangling of the angiopathy
paradigm, ROS production sites, ROS-redox metabolism, or
ROS-induced inflammation pathways might become new tar-
gets for innovative classes of drugs to treat mitochondrial
migraine in m.3243A>G patients. Such new drugs might
either act alone or might be used as adjuvant to current treat-
ment modalities.
8 | FUTURE PERSPECTIVES
The exact sequence of events and the relative importance of
factors underlying migraine in m.3243A>G patients are still
enigmatic. However, substantial evidence exists in man that
dysfunctional mitochondria in both the vascular, the smooth
muscle cells as the neuronal system and the interaction
between these are presumably at the starting point of the cas-
cade that leads to migraine. Of the many consequences of
OXPHOS dysfunction, reactive oxygen species overproduc-
tion and the thereby caused chemical neuroinflammation
might become new targets for ameliorating migraine in
m.3243A>G patients. Whether a similar cascade of event is
applicable to other mitochondrial diseases associated with
migraine warrants further studies.
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